secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001493152-25-008457
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports FY2024 net loss $18.6M, OS benefit 13mo for IMNN-001, Phase 3 start Q1 2025
--------------------------------------------------------------------------------

- Net loss $18.6M ($1.62/share) in 2024 vs $19.5M in 2023; cash $5.9M at year-end, sufficient into late Q2 2025.
- OVATION 2: median OS 13 months (HR 0.69) with IMNN-001 + chemo vs SOC alone; >1/3 survived >36 months.
- Phase 3 pivotal trial of IMNN-001 to begin Q1 2025 after positive End-of-Phase 2 and CMC meetings with FDA.
- New CMO Douglas V. Faller, M.D., Ph.D. appointed Feb 18, 2025; leads clinical strategy for IMNN-001.
- PlaCCine vaccine Phase 1: IMNN-101 safe, induced 2-4x NAb titers; seeks partners for further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/0001493152-25-008457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315225008457/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer